Background {#Sec1}
==========

Cancer is a worldwide public health problem, and considerable parts of death are due to cancer every year. It is reported that one fourth deaths in the United States is caused by cancer \[[@CR1]\]. According to the latest cancer data from the GLOBOCAN website, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide \[[@CR2]\]. The statistical data of cancer in 2017 shows that 1,688,780 new cancer cases (836,150 males and 852,630 females) are expected to be diagnosed in the United States, and 600,920 Americans (318,420 males and 282,500 females) are expected to die of cancer \[[@CR3]\]. For all sites combined, both the incidence rate and death rate are higher in males than those in females, and the most commonly diagnosed cancers are lung cancer, prostate cancer, breast cancer, and colon cancer \[[@CR3]\].

Pathogenesis of cancer has been studied worldwide for a long time, generating different theories, such as the gene mutation, oxidative stress, and ionization radiation theories. Single nucleotide polymorphisms (SNPs) on different genes have been detected for finding specific biomarkers in different cancers. Ataxia telangiectasia-mutated (ATM) gene is one of the most frequently studied genes in cancer occurrence and progression. Mutation on *ATM* leads to the human autosomal recessive disorder, ataxia-telangiectasia (A-T), resulting in high cellular radiosensitivity, chromosomal instability, immunodeficiency, and cancer predisposition \[[@CR4], [@CR5]\]. Lymphomas and leukemia are predominant in all types of cancer in A-T patients, and the cancer incidence rate in black A-T patients is as more than two times as that in whites \[[@CR6], [@CR7]\]. ATM gene is located in human chromosome 11q22--23, spans over 160 kb DNA, and encodes a 315 kDa protein. As a member belonging to the phosphoinositide 3-kinase (PI3-K)-related protein kinase family, ATM is activated by a series of cellular stress events, such as DNA double-strand break (DSB), reactive oxygen species, hypotonic stress, and chloroquine \[[@CR8]\]. ATM is involved in important life processes, including DNA repair, cell cycle regulation, neuroprotection, immunity, metabolism, longevity, and fertility \[[@CR8]\].

Several *ATM* polymorphism loci have been studied in different types of cancer, including rs1801516, which is a common nonsynonymous variant on this gene. Genome-wide association studies (GWAS) have identified rs1801516 as a susceptibility locus for melanoma \[[@CR9]\]. Large-sample case-control studies have assessed effects of this polymorphism on risk of breast cancer, prostate cancer, rectal cancer, bladder cancer, lung cancer, pancreatic cancer, and thyroid cancer. Meta-analyses have also been performed to assess *ATM* rs1801516 polymorphism and cancer predisposition, but the results are inconsistent \[[@CR10]--[@CR14]\].

We performed this meta-analysis to further identify the association between rs1801516 polymorphism and cancer risk using larger sample size than ever before, and using the trial sequential analysis (TSA) to give more comprehensive conclusions.

Methods {#Sec2}
=======

We conducted this meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR15]\].

Search strategy {#Sec3}
---------------

Systematic search of publications was performed in PubMed, Web of Science, and Embase datasets (last search on November 18, 2017). Because of different nomenclatures for SNP, we took all the names that might be used in different studies of this SNP into consideration in our searching terms: "(rs1801516 or G5557A or 5557G\>A or 5557 G/A or Asp1853Asn or D1853N or G1853A) and (cancer or carcinoma or malignancy)".

Inclusion criteria {#Sec4}
------------------

Studies included in this meta-analysis met the following criteria: (1) A human study with full text available; (2) A study on *ATM* rs1801516 polymorphism and cancer risk; (3) Using a case-control study design; (4) Using healthy subjects without malignant diseases as controls; (5) Genotype data is sufficient for odds ratio (*OR*) and 95% confidence interval (*CI*) estimation. In addition, we screened the reference lists of all the relevant studies, including eligible studies, reviews and meta-analyses, and only original articles published in English were included.

Data extraction {#Sec5}
---------------

For each included study, the following information was extracted: the first author, year of publication, country, region-specified population, cancer type, source of controls, matching criteria of controls, family history, genotyping method, Hardy-Weinberg equilibrium (HWE) in controls, minor allele frequency (MAF) in cases and controls, sample size, and numbers of cases and controls with different genotype. Region-specified population in our meta-analysis was defined geographically as European, North American, South American, Asian, and Oceanian. Population-based controls (PBC) and hospital-based controls (HBC) were classified in our meta-analysis: blood donors and controls recruited from birth cohort, general population, and community are defined as PBC; and controls recruited from hospitals, clinics, research institutions, and biorepository were defined as HBC.

Quality assessment {#Sec6}
------------------

Two authors (YG and JS) assessed the quality of each study independently according to the Newcastle-Ottawa Scale (NOS) for case-control studies \[[@CR16]\]. A study can be awarded a maximum score of 9: 4 assigned for selection, 2 for comparability, and 3 for exposure. When inconsistency existed between the two authors, the third author (SQ) was requested to reassess the score of quality.

Statistical analysis {#Sec7}
--------------------

Allele and genotype frequencies in controls were calculated for each study to evaluate the HWE using chi-square test. Association between rs1801516 polymorphism and cancer risk was assessed by *OR* and corresponding 95% *CI* calculated from logistic regression. For each analysis, stratified or pooled, five comparisons were conducted, including dominant model (GA/AA vs GG), codominant model (GA vs GG and AA vs GG), recessive (AA vs GG/GA), and overdominant model (GA vs GG/AA). For studies of Sommer SS et al. \[[@CR17]\], Gonzalez-Hormazabal P et al. \[[@CR18]\], Maillard S et al. \[[@CR19]\], and Calderon-Zuniga Fdel C et al. \[[@CR20]\], no AA genotype was detected in either case or control group; thus, these studies were excluded in comparisons of AA vs GG and AA vs GA/GG. For studies of Yang H et al. \[[@CR21]\], Bretsky P et al. \[[@CR22]\], and Hirsch AE et al. \[[@CR23]\], frequencies of GG and GA genotypes were presented together as GG/GA; thus, only association under recessive model was evaluated for these studies. For study of Xu L et al. \[[@CR24]\], frequencies of GA and AA genotypes were presented together as GA/AA; thus, only association under dominant model was evaluated for this study. Subgroup analyses were performed by cancer type, region-specified population, source of control, matching status of controls, family history, sample size, and HWE in controls. Heterogeneity among studies was evaluated using *Q* test and *I*^*2*^ statistics. Fixed effect model (Mantel-Haenszel method) was used to calculate *OR* and 95% *CI* when *P* value of *Q* test was more than 0.10 or *I*^*2*^ value was less than 50%; otherwise, random effect model (DerSimonian-Laird method) was used. When the meta-analysis included 10 studies or more, publication bias was estimated using the visualizing Begg's funnel plot, in which the *log(OR)* and its standard error of each study were indicated as Y- and X- axes respectively. An asymmetric funnel plot implied a possible publication bias. Furthermore, Egger's linear regression test was utilized to determine the significance of asymmetry (*P* \< 0.05 was considered to represent significant publication bias). Sensitivity analysis was performed with one study omitted at each time.

All analyses were performed using Stata 12.0, and two-sided tests with *P* value less than 0.05 was considered statistically significant unless otherwise specified.

Trial sequential analysis {#Sec8}
-------------------------

Because of sparse data and repeated significance testing, meta-analyses may lead to type I error for the presence of systematic errors (bias) or random errors (play of chance) \[[@CR25]--[@CR27]\]. To assess our meta-analysis comprehensively, we performed TSA using the novel TSA software \[[@CR28]\] to calculate the required information size (sample size) with an adjusted significance level. Briefly, we calculated the required information size on the basis of an overall type I error of 5%, an overall type II error of 20% (a power of 80%), and a relative risk reduction of 20%. Two-sided graphs were plotted using dotted black lines indicating boundaries for significance in a conventional meta-analysis, blue line indicating the cumulative *Z*-score, and red lines sloping inwards indicating trial sequential monitoring boundaries using adjusted *P* values.

Results {#Sec9}
=======

Study characteristics {#Sec10}
---------------------

After strict screening, 34 eligible studies with 12,879 cases and 18,054 controls were identified in our meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). In studies of Xu L et al. \[[@CR24]\], Tommiska J et al. \[[@CR29]\], and Akulevich NM et al. \[[@CR30]\], two independent case-control studies were presented respectively; thus, each study was treated separately in our meta-analysis. For study of Xu L et al. \[[@CR24]\], two parts of controls (HBC and PBC) were included; for study of Tommiska J et al. \[[@CR29]\], two parts of cases (familial and unselected cases) were included; for study of Akulevich NM et al. \[[@CR30]\], based on the condition of ionizing radiation (IR)-exposed or not, two separate studies were included, namely IR-induced papillary thyroid cancers (PTCs) vs IR-exposed controls, and sporadic PTCs vs non-exposed controls. Finally, 37 studies were included in the following analyses: 14 studies concentrated on effect of rs1801516 polymorphism on breast cancer risk \[[@CR17], [@CR18], [@CR20], [@CR22], [@CR23], [@CR29], [@CR31]--[@CR37]\], nine on thyroid cancer risk \[[@CR19], [@CR24], [@CR30], [@CR38]--[@CR41]\], three on cervical cancer risk \[[@CR42]--[@CR44]\], two on colorectal cancer risk \[[@CR45], [@CR46]\], two on lung cancer risk \[[@CR21], [@CR47]\], one on bladder cancer risk \[[@CR48]\], one on head and neck cancer risk \[[@CR49]\], one on malignant melanoma risk \[[@CR50]\], one on ovarian cancer risk \[[@CR51]\], one on pancreatic cancer risk \[[@CR52]\], one on prostate cancer risk \[[@CR53]\], and one on renal cell cancer risk \[[@CR54]\], respectively. Main characteristics of these studies are shown in Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1. Region-specified population was defined geographically in the 37 studies, 19 of which was European, 12 of which was North American, two of which was South American, three of which was Asian, and one of which was Oceanian. Cases in seven studies had a family history, and cases in the other 30 studies were unselected. Controls in 14 studies were HBC, controls in 17 studies were PBC, and six studies didn't report the source of controls. A total of 25 studies had controls matched to cases for different factors; whereas, 12 studies had controls not matched to cases in that the controls were randomly selected. Genotyping methods were diverse, including real time polymerase chain reaction (RT-PCR), PCR-restriction fragment length polymorphism (PCR-RFLP), TaqManSNP (TaqMan), direct sequencing, microarray, and ten other methods. NOS scores of the included studies ranged from six to nine, indicating that the quality of studies in our meta-analysis is high.Fig. 1Flow chart of the process of study identification and selectionTable 1Main characteristics of the eligible studies included in the meta-analysisFirst authorYearCountryRegion-specified populationCancer typeSource of controlsMatched controlsFamily historyNNOS ScoreCasesControlsMaillet P \[[@CR45]\]2000SwissEuropeanColorectal cancerPBCNoYes471637Dork T \[[@CR34]\]2001GermanyEuropeanBreast cancerPBCYesNo10005008Sommer SS \[[@CR17]\]2002USANorth AmericanBreast cancerHBCYesNo43437Angele S \[[@CR33]\]2003FranceEuropeanBreast cancerPBCYesNo2543128Bretsky P \[[@CR22]\]2003USANorth AmericanBreast cancerPBCYesNo4284269Angele S \[[@CR53]\]2004UKEuropeanProstate cancerPBCNoNo6374457Buchholz TA \[[@CR37]\]2004USANorth AmericanBreast cancerPBCNoNo585287Kristensen AT \[[@CR46]\]2004NorwayEuropeanColorectal cancerPBCNoNo15135267Heikkinen K \[[@CR35]\]2005FinlandEuropeanBreast cancerPBCYesYes1213069Landi S \[[@CR47]\]2006Six countries^c^EuropeanLung cancerHBCYesNo2993178Renwick A \[[@CR36]\]2006UKEuropeanBreast cancerPBCNoYes4435217Tommiska J ^a^ \[[@CR29]\]2006FinlandEuropeanBreast cancerNRYesYes7867087Tommiska J ^b^ \[[@CR29]\]2006FinlandEuropeanBreast cancerNRYesNo8847087Wu X \[[@CR48]\]2006USANorth AmericanBladder cancerHBCYesNo6966298Yang H \[[@CR21]\]2007USANorth AmericanLung cancerHBCYesNo5565568Gonzalez-Hormazabal P \[[@CR18]\]2008ChileSouth AmericaBreast cancerHBCYesYes1262008Hirsch AE \[[@CR23]\]2008USANorth AmericanBreast cancerHBCYesNo37957Margulis V \[[@CR54]\]2008USANorth AmericanRenal cell cancerPBCYesNo3263359Schrauder M \[[@CR32]\]2008GermanyEuropeanBreast cancerHBCYesNo5145118Tapia T \[[@CR31]\]2008ChileSouth AmericaBreast cancerPBCNoYes952007Akulevich NM ^a^ \[[@CR30]\]2009Russian, BelarusEuropeanThyroid cancerPBCYesNo1231989Akulevich NM ^b^ \[[@CR30]\]2009RussiaEuropeanThyroid cancerPBCYesNo1323989Li D \[[@CR52]\]2009USANorth AmericanPancreatic cancerHBCYesNo7347808Oliveira S \[[@CR43]\]2011PortugueseEuropeanCervical cancerHBCNoNo1492806Al-Hadyan KS \[[@CR49]\]2012Saudi ArabiaAsianHead and neck cancerNRNoNo1562516Xu L ^a^ \[[@CR24]\]2012USANorth AmericanThyroid cancerHBCNoNo3035116Xu L ^b^ \[[@CR24]\]2012USANorth AmericanThyroid cancerPBCYesNo2893749Alsbeih G \[[@CR42]\]2013Saudi ArabiaAsianCervical cancerNRYesNo1001008Pena-Chilet M \[[@CR50]\]2013SpanishEuropeanMalignant melanomaHBCYesNo5663477Calderon-Zuniga Fdel C \[[@CR20]\]2014MexicoNorth AmericanBreast cancerHBCNoYes94966Damiola F \[[@CR39]\]2014BelarusEuropeanThyroid cancerPBCYesNo833249Wojcicka A \[[@CR38]\]2014PolandEuropeanThyroid cancerHBCNoNo160318446Maillard S \[[@CR19]\]2015FranceOceanianThyroid cancerPBCYesNo1772759Pereda CM \[[@CR41]\]2015CubaNorth AmericanThyroid cancerPBCYesNo2032129Tecza K \[[@CR51]\]2015PolandEuropeanOvarian cancerHBCYesNo2253487Halkova T \[[@CR40]\]2016Czech RepublicEuropeanThyroid cancerNRNoNo2093746Al-Harbi NM \[[@CR44]\]2017Saudi ArabiaAsianCervical cancerNRYesNo2323137*HBC*, hospital-based case--controls; *PBC,* population-based case--controls; *NR*, not report^a,b^ Two independent case-control studies were presented for the same original study^c^This study was conducted in six Central and Eastern European countries: Czech Republic, Hungary, Poland, Romania, Russia, and Slovakia

HWE in controls and MAF in cases and controls for each study were obtained after reading the full text or calculated according to the genotype data (Table [2](#Tab2){ref-type="table"}). As a result, rs1801516 genotype distribution of controls was in HWE for 30 studies, and was not in HWE for four studies; besides, genotype distribution could not be obtained for three studies. Therefore, to assess the potential influence of HWE on the overall results, subgroup analysis by HWE in controls was performed. For study of Calderon-Zuniga Fdel C et al., the minor allele A was not detected in controls.Table 2Genotype distribution in cases and controls of the eligible studiesFirst authorYearCasesControlsHWE in controlsMAF (cases/controls)GGGAAAGGGAAAMaillet P \[[@CR45]\]2000341301204030.8740.138 / 0.141Dork T \[[@CR34]\]2001753235124227440.7050.130 / 0.082Sommer SS \[[@CR17]\]20023850321100.3360.058 / 0.128Angele S \[[@CR33]\]20032406571925660.4330.127 / 0.134Bretsky P \[[@CR22]\]2003335^c^47329^c^47NANAAngele S \[[@CR53]\]200445715318309124120.9170.150 / 0.166Buchholz TA \[[@CR37]\]200439172394119150.1070.181 / 0.141Kristensen AT \[[@CR46]\]200499502241310081050.9830.179 / 0.173Heikkinen K \[[@CR35]\]200568449174109230.3080.256 / 0.253Landi S \[[@CR47]\]20062057372386330.6020.153 / 0.113Renwick A \[[@CR36]\]2006339986371131190.0880.124 / 0.162Tommiska J ^a^ \[[@CR29]\]200648528533404260380.6480.219 / 0.239Tommiska J ^b^ \[[@CR29]\]200646927633404260380.6480.220 / 0.239Wu X \[[@CR48]\]200643415618439136170.1090.158 / 0.144Yang H \[[@CR21]\]2007537^c^7536^c^100.590NAGonzalez-Hormazabal P \[[@CR18]\]20081002601742600.3260.103 / 0.065Hirsch AE \[[@CR23]\]200829^c^878^c^17NANAMargulis V \[[@CR54]\]20082546452498150.5830.115 / 0.136Schrauder M \[[@CR32]\]2008406999369129130.6680.114 / 0.152Tapia T \[[@CR31]\]2008741911831520.0150.112 / 0.048Akulevich NM ^a^ \[[@CR30]\]2009952521385370.5010.119 / 0.169Akulevich NM ^b^ \[[@CR30]\]200910524329390150.0200.114 / 0.151Li D \[[@CR52]\]20095241861856520080.0340.152 / 0.140Oliveira S \[[@CR43]\]20111133151947970.7550.138 / 0.166Al-Hadyan KS \[[@CR49]\]20121312322183300.2650.087 / 0.066Xu L ^a^ \[[@CR24]\]201223964^d^392119^d^\> 0.05NAXu L ^b^ \[[@CR24]\]201224445^d^30569^d^\> 0.05NAAlsbeih G \[[@CR42]\]20139082881200.5230.060 / 0.060Pena-Chilet M \[[@CR50]\]201334991923268110.0400.121 / 0.145Calderon-Zuniga Fdel C \[[@CR20]\]2014821209600NA0.060 / 0.000Damiola F \[[@CR39]\]201463611776670.7780.057 / 0.160Wojcicka A \[[@CR38]\]20141261319231455357320.0660.114 / 0.114Maillard S \[[@CR19]\]2015164110262800.8050.031 / 0.015Pereda CM \[[@CR41]\]20151534401624220.6900.112 / 0.112Tecza K \[[@CR51]\]20151536462547650.8000.170 / 0.128Halkova T \[[@CR40]\]20161584552848190.2700.132 / 0.132Al-Harbi NM \[[@CR44]\]20172012832753800.2530.073 / 0.061*HWE*, hardy-weinberg equilibrium*; MAF*, minor allele frequency; *NA*, data was unavailable^a,b^Two independent case-control studies were presented for the same original study^c^number of GG + GA^d^number of GA + AA

Main results of meta-analyses {#Sec11}
-----------------------------

The pooled and subgroup meta-analyses of associations between rs1801516 polymorphism and cancer susceptibility are shown in Table [3](#Tab3){ref-type="table"}. Overall, no significant association was found under any model of inheritance (AA vs GG + GA: *OR* = 0.91, 95% *CI*, 0.78--1.07; AA+GA vs GG: *OR* = 1.00, 95% *CI*, 0.90--1.11; AA vs GG: *OR* = 0.89, 95% *CI*, 0.75--1.06; GA vs GG: *OR* = 1.01, 95% *CI*, 0.91--1.13; GG + AA vs GA: *OR* = 1.00, 95% *CI*, 0.88--1.10). In subgroup analyses by region-specified population, significant associations were found in European (AA vs GG + GA: *OR* = 0.79, 95% *CI*, 0.65--0.96, *P* = 0.017; AA vs GG: *OR* = 0.79, 95% *CI*, 0.65--0.96, *P* = 0.017), South American (AA+GA vs GG: *OR* = 2.15, 95% *CI*, 1.37--3.38, *P* = 0.001; GA vs GG: *OR* = 2.19, 95% *CI*, 1.38--3.47, *P* = 0.001; GG + AA vs GA: *OR* = 0.46, 95% *CI*, 0.29--0.72, *P* = 0.001), and Asian (AA vs GG + GA: *OR* = 7.45, 95% *CI*, 1.31--42.46, *P* = 0.024; AA vs GG: *OR* = 7.40, 95% *CI*, 1.30--42.19, *P* = 0.024). In subgroup analyses by cancer types, significant decreased risk of breast cancer was found for those carrying AA genotype (AA vs GG: *OR* = 0.76, 95% *CI*, 0.59--0.98, *P* = 0.035). In subgroup analyses by family history, AA carriers had a significant decreased risk compared with GG carriers in those with family history (AA vs GG: *OR* = 0.68, 95% *CI*, 0.47--0.98, *P* = 0.039), and a borderline significance was found for AA vs GG + GA (*OR* = 0.70, 95% *CI*, 0.48--1.00, *P* = 0.051).Table 3Overall and subgroup meta-analyses of association between rs1801516 polymorphism and cancer susceptibility under different modelsGroupAA vs GG + GAAA+GA vs GGAA vs GGGA vs GGGG + AA vs GA*OR* (95% CI)*I*^*2*^ (%)*P* ~h~*OR* (95% CI)*I*^*2*^ (%)*P* ~h~*OR* (95% CI)*I*^*2*^ (%)*P* ~h~*OR* (95% CI)*I*^*2*^ (%)*P* ~h~*OR* (95% CI)*I*^*2*^ (%)*P* ~h~**Overall**0.91 (0.78, 1.07)\< 0.10.6161.00 (0.90, 1.11)60.8\< 0.0010.89 (0.75, 1.06)5.80.3781.01 (0.91, 1.13)77.14\< 0.0011.00 (0.88, 1.10)74.4\< 0.001**Region-specified population** European**0.79 (0.65, 0.96)**\< 0.10.8480.94 (0.82, 1.07)65.6\< 0.001**0.79 (0.65, 0.96)**\< 0.10.6770.95 (0.84, 1.08)61.9\< 0.0011.04 (0.92, 1.18)60.0\< 0.001 North American1.09 (0.82, 1.45)\< 0.10.5661.02 (0.90, 1.15)43.60.0771.32 (0.85, 2.06)\< 0.10.4081.03 (0.80, 1.32)52.30.0500.97 (0.76, 1.25)52.50.049 South American1.07 (0.1, 11.88)----**2.15 (1.37, 3.38)**16.60.2741.24 (0.11, 13.84)----**2.19 (1.38, 3.47)**33.20.221**0.46 (0.29, 0.72)**32.70.223 Asian**7.45 (1.31, 42.46)**\< 0.10.9561.11 (0.79, 1.58)\< 0.10.719**7.40 (1.30, 42.19)**\< 0.10.9491.00 (0.70, 1.43)\< 0.10.5921.02 (0.71, 1.46)\< 0.10.584 Oceanian1.83 (0.55, 6.05)----2.20 (0.87, 5.58)----------2.20 (0.87, 5.58)----0.46 (0.18, 1.16)----**Cancer type** Breast cancer0.84 (0.68, 1.04)\< 0.10.7771.09 (0.86, 1.38)78.0\< 0.001**0.76 (0.59, 0.98)**\< 0.10.6321.11 (0.87, 1.41)76.4\< 0.0010.90 (0.71, 1.13)75.3\< 0.001 Thyroid cancer0.73 (0.48, 1.11)\< 0.10.8860.87 (0.71, 1.07)52.30.0330.71 (0.47, 1.08)\< 0.10.8300.89 (0.67, 1.18)60.60.0181.11 (0.84, 1.47)59.10.023 Cervical cancer2.29 (0.89, 5.91)\< 0.10.3790.86 (0.63, 1.18)\< 0.10.4432.13 (0.83, 5.48)5.80.3460.79 (0.57, 1.09)\< 0.10.4891.29 (0.93, 1.79)\< 0.10.494 Colorectal cancer0.44 (0.12, 1.59)\< 0.10.9531.13 (0.83, 1.54)\< 0.10.8740.47 (0.13, 1.69)\< 0.10.9661.20 (0.87, 1.64)\< 0.10.8990.82 (0.60, 1.12)\< 0.10.903 Lung cancer1.22 (0.35, 4.20)55.40.1341.41 (0.97, 2.05)----2.71 (0.69, 10.61)----1.35 (0.92, 1.98)----0.76 (0.52, 1.12)----**Source of controls** PBC0.83 (0.65, 1.07)\< 0.10.8580.99 (0.81, 1.21)70.8\< 0.0010.75 (0.55, 1.03)\< 0.10.7711.03 (0.83, 1.28)70.8\< 0.0010.96 (0.78, 1.19)69.9\< 0.001 HBC1.04 (0.80, 1.36)17.20.2851.02 (0.86, 1.20)62.50.0021.06 (0.80, 1.42)36.20.1401.03 (0.86, 1.23)62.20.0030.98 (0.82, 1.17)60.80.004 NR0.88 (0.64, 1.20)24.00.2540.93 (0.82, 1.06)\< 0.10.8270.86 (0.63, 1.18)26.20.2380.93 (0.82, 1.07)\< 0.10.9281.06 (0.93, 1.20)\< 0.10.944**Matched controls** Yes0.95 (0.79, 1.14)\< 0.10.5140.97 (0.84, 1.12)64.8\< 0.0010.93 (0.75, 1.15)180.2380.99 (0.86, 1.14)62.4\< 0.0011.01 (0.88, 1.16)60.5\< 0.001 No0.82 (0.59, 1.12)\< 0.10.5671.02 (0.86, 1.21)54.90.0110.81 (0.59, 1.11)\< 0.10.5651.06 (0.87, 1.29)58.20.0080.94 (0.77, 1.14)57.90.008**Family history** Yes0.70 (0.48, 1.00)\< 0.10.5741.20 (0.85, 1.71)73.10.001**0.68 (0.47, 0.98)**\< 0.10.5191.25 (0.88, 1.77)71.20.0020.80 (0.57, 1.12)69.90.003 No0.98 (0.82, 1.16)\< 0.10.6340.97 (0.87, 1.09)57.9\< 0.0010.97 (0.79, 1.18)5.20.390.98 (0.87, 1.11)57.5\< 0.0011.02 (0.90, 1.14)56\< 0.001**Sample size**  \< 10000.95 (0.75, 1.20)\< 0.10.6010.99 (0.85, 1.15)56.8\< 0.0010.89 (0.67, 1.20)4.70.3991.01 (0.85, 1.19)56.4\< 0.0010.99 (0.84, 1.17)54.90.001  \> 10000.89 (0.72, 1.10)2.00.4201.01 (0.87, 1.17)71.6\< 0.0010.89 (0.71, 1.11)18.10.2821.02 (0.88, 1.18)69.90.0010.98 (0.84, 1.13)68.70.001**HWE in controls** Yes0.87 (0.73, 1.05)\< 0.10.740.99 (0.89, 1.10)57.5\< 0.0010.87 (0.72, 1.05)\< 0.10.581.00 (0.89, 1.12)56.7\< 0.0010.99 (0.89, 1.11)54.9\< 0.001 No1.09 (0.64, 1.84)56.00.0781.06 (0.70, 1.61)76.30.0050.95 (0.36, 2.50)58.30.0661.08 (0.72, 1.63)74.40.0080.92 (0.62, 1.38)73.50.010 NR1.03 (0.69, 1.52)\< 0.10.63129.24 (1.71, 501.48)----------29.24 (1.71, 501.48)----**0.03 (0.00, 0.59)**----*HBC*, hospital-based case--controls; *PBC*, population-based case--controls; *NR*, not report*P*~h~, *P* value of *Q* test for heterogeneitySignificant *OR*s (95% CIs) were in bold

Heterogeneity analysis {#Sec12}
----------------------

We applied *Q* test and *I*^*2*^ statistics to evaluate the heterogeneity of our meta-analysis. Our results showed significant heterogeneity among studies for AA+GA vs GG (*I*^*2*^ = 60.8%, *P* \< 0.001), GA vs GG (*I*^*2*^ = 77.1%, *P* \< 0.001), and GG + AA vs GA (*I*^*2*^ = 74.4%, *P* \< 0.001) models (Table [3](#Tab3){ref-type="table"}). To further investigate the source of heterogeneity, we performed meta-regression analysis by region-specified population, cancer type, source of controls, matched controls or not, family history, sample size, and HWE in controls. As a result, family history was a source of heterogeneity for AA+GA vs GG (*P* = 0.040, 59% *CI*, 0.204--7.804) and GA vs GG (*P* = 0.044, 59% *CI*, 0.113--8.055), suggesting that family history may explain the among-studies' heterogeneity under these two models. However, no factor was detected as a source of heterogeneity for GG + AA vs GA (Table [4](#Tab4){ref-type="table"}).Table 4The meta-regression results of the association between the rs1801516 polymorphism and cancer riskComparisonsCoef.Std. Err.*tP*95% *CIτ* ^2^*I*^2^ res (%)Adj *R*^2^ (%)F*P* ~J~AA+GA vs GG Region-specified population0.20993.570−7.2800.5800.676  European−1.2454.907−0.2500.801(−11.280, 8.790)  North American1.6465.0430.3300.747(−8.668, 11.959)  South American0.1285.8530.0200.983(−11.843, 12.098)  Asian−1.1325.520− 0.2100.839(−12.421, 10.157)  Oceanianreferentreferentreferentreferentreferent Cancer type0.22194.150−13.6900.3600.870  Breast cancer2.2733.7440.6100.549(−5.396, 9.942)  Cervical cancer−0.2204.474− 0.0500.961(−9.383, 8.944)  Lung cancer0.3045.9960.0500.960(−11.979, 12.587)  Thyroid cancer−0.1473.830− 0.0400.970(−7.993, 7.698)  Other cancer−0.0493.927−0.0100.990(−8.093, 7.996)  Colorectal cancerreferentreferentreferentreferentreferentSource of controls2.0661.9651.0500.303(−1.974, 6.106)0.24694.5900.040Matched controls−2.2821.640−1.3900.174(−5.624, 1.059)0.18993.4102.740Family history4.00381.8662.150**0.040(0.204, 7.804)**0.17493.40010.750Sample size−1.0691.8193−0.590.561(−4.774, 2.637)0.20093.410−2.600HWE in controls−0.1750.2304−0.760.454(−0.645, 0.295)0.00171.000−8.060GA vs GG Region-specified population0.21993.930−4.2900.8000.538  European−1.2335.004−0.2500.807(−11.500, 9.033)  North American2.5285.2170.4800.632(−8.176, 13.231)  South American0.2395.9690.0400.968(−12.009, 12.487)  Asian−1.2565.629−0.2200.825(−12.807, 10.295)  Oceanianreferentreferentreferentreferentreferent Cancer type0.24194.510−15.0000.3400.887  Breast cancer2.2413.8950.5800.570(−5.764, 10.247)  Cervical cancer−0.4004.654−0.0900.932(−9.967, 9.167) Lung cancer0.1676.2380.0300.979(−12.656, 12.990)  Thyroid cancer−0.1764.087−0.0400.966(−8.576, 8.225)  Other cancer−0.1474.086−0.0400.972(−8.545, 8.251)  Colorectal cancerreferentreferentreferentreferentreferentSource of controls2.2262.1251.0500.305(−2.160, 6.612)0.26794.9500.030Matched controls−2.5471.753−1.4500.157(−6.127, 1.033)0.20293.7603.530Family history4.0841.9442.100**0.044(0.113, 8.055)**0.18793.75010.770Sample size−1.1781.903−0.6200.541(−5.065, 2.709)0.21593.760−2.580HWE in controls−0.2060.250−0.8200.417(−0.717, 0.305)0.00171.820−9.320GG + AA vs GA Region-specified population0.00168.410−6.3900.8000.534  European0.6590.7170.9200.366(−0.813, 2.131)  North American0.5950.7360.8100.426(−0.915, 2.106)  South American0.0060.8160.0100.994(−1.668, 1.680)  Asian0.6180.7810.7900.435(−0.984, 2.221)  Oceanianreferentreferentreferentreferentreferent Cancer type0.00169.840−42.3500.5700.719  Breast cancer0.1670.4070.4100.685(−0.669, 1.003)  Cervical cancer0.5000.5001.0000.327(−0.529, 1.529)  Lung cancer−0.0650.615−0.1100.917(−1.329, 1.199)  Thyroid cancer0.4580.4281.0700.294(−0.422, 1.338)  Other cancer0.1930.4180.4600.648(−0.666, 1.052)  Colorectal cancerreferentreferentreferentreferentreferentSource of controls−0.0280.240−0.1200.907(−0.523, 0.467)0.00273.660−13.140Matched controls0.1300.1860.7000.491(−0.250, 0.509)0.00167.720−21.020Family history−0.2140.221−0.9700.340(−0.666, 0.237)0.00167.750−18.530Sample size−0.0860.184−0.4700.643(−0.463, 0.290)0.00167.700−15.790HWE in controls0.0550.2630.2100.836(−0.484, 0.594)0.00168.690−17.640*P*~J~: *P* value of the joint test for all variablesSignificant 95% *CI*s and *P* values were in bold

Publication bias {#Sec13}
----------------

Begg's funnel plot and Egger's linear regression test were used to assess the publication bias of studies in our meta-analysis. The shape of the funnel plots under four models seemed symmetrical (Fig. [2](#Fig2){ref-type="fig"}), and the results of Egger's test revealed no evidence of significant publication bias (AA vs GG + GA: *P* = 0.266; AA+GA vs GG: *P* = 0.505; AA vs GG: *P* = 0.201; GA vs GG: *P* = 0.574; GG + AA vs GA: *P* = 0.587).Fig. 2Funnel plots for publication bias of the meta-analysis on rs1801516 polymorphism and overall cancer risk. **a** recessive model: AA vs GG + GA; **b** dominant model: AA+GA vs GG; **c** codominant model: AA vs GG; **d** codominant model: GA vs GG; **e** overdominant model: AA+GG vs GA

Sensitivity analyses {#Sec14}
--------------------

We performed sensitivity analysis by excluding one study at each time to evaluate the influence of each individual study on the overall *OR*s and 95% *CI*s. The results showed that the pooled *OR*s and 95% *CI*s under any model of inheritance were not substantially altered after omitting any individual study (Fig. [3](#Fig3){ref-type="fig"}), suggesting that the results of our meta-analysis are credible.Fig. 3Sensitivity analyses of the studies. **a** recessive model: AA vs GG + GA; **b** dominant model: AA+GA vs GG; **c** codominant model: AA vs GG; **d** codominant model: GA vs GG; **e** overdominant model: AA+GG vs GA

Trial sequential analysis {#Sec15}
-------------------------

The results of TSA under four models (five comparisons) are shown in Fig. [4](#Fig4){ref-type="fig"}, and they were consistent with the results of the conventional meta-analyses. The blue lines of cumulative *Z*-score didn't cross the trial sequential monitoring boundaries (red lines sloping inwards), suggesting there is no significant association between rs1801516 polymorphism and cancer risk. Moreover, sample sizes in our overall meta-analyses were all more than the required information sizes (AA vs GG + GA: 6429; AA+GA vs GG: 20201; AA vs GG: 8219; GA vs GG: 19885; GG + AA vs GA: 19209), suggesting that the results of our meta-analyses are reliable.Fig. 4Trial sequential analysis of the association between rs1801516 polymorphism and overall cancer risk. The required information size was calculated based on a two side *α* = 5%, *β* = 25% (power 80%), and a relative risk reduction of 20%. **a** recessive model: AA vs GG + GA; **b** dominant model: AA+GA vs GG; **c** codominant model: AA vs GG; **d** codominant model: GA vs GG; **e** overdominant model: AA+GG vs GA

Discussion {#Sec16}
==========

Studies of rs1801516 polymorphism on cancer risk have been performed for more than ten cancers in previous studies, and breast cancer and thyroid cancer are the two most studied ones. So far, three meta-analyses have been performed on association between rs1801516 polymorphism and breast cancer risk \[[@CR11], [@CR12], [@CR14]\], and two meta-analysis have been performed on the association between rs1801516 polymorphism and thyroid cancer risk \[[@CR10], [@CR55]\]. Moreover, one meta-analysis focused on this polymorphism and cancer risk despite of cancer types, but it was stratified by the status of radiation exposure \[[@CR13]\]. In our meta-analysis, we assessed the association between rs1801516 polymorphism and overall cancer risk for the first time. We found that no significant association existed under any model of inheritance in the overall analysis. Our result was consistent with the finding of the previous study on rs1801516 polymorphism and cancer risk in population without radiation exposure \[[@CR13]\]. Therefore, rs1801516 polymorphism may be not associated with overall cancer risk.

In subgroup analyses by region-specified population, cancer types, and family history, significant associations were found for European, South American, Asian, breast cancer, and those with family history. Firstly, results of subgroup analysis by region-specified population were interesting. In European and Asian, reversed results were observed for AA vs GG + GA and AA vs GG. The homozygote AA showed a protective effect against cancer in European, but it presented a susceptible effect for cancer in Asian. Therefore, rs1801516 polymorphism may exert inversed effect on European and Asian. In South American, the other three models (AA+GA vs GG, GA vs GG, and GG + AA vs GA) were significant. Susceptible effect for cancer was observed for AA+GA vs GG and GA vs GG, and protective effect against cancer was observed for GG + AA vs GA. We infer that the results in South American may be attributed to the heterozygote GA, which may be a risk genotype of cancer in South American. Populations from different region may be ethnically different, and this difference may in turn have an influence on cancer susceptibility. Studies have revealed cancer trends differed from ethnicity \[[@CR56]--[@CR58]\], and patients of different ethnicity presents different cancer phenotypes \[[@CR59], [@CR60]\]. Besides, discrepancy in distribution of rs1801516 genotype may exist in different populations. Secondly, subgroup analysis by cancer types in our study indicated that AA homozygotes have a relative low risk of breast cancer compared with GG carriers. Three previous meta-analyses \[[@CR11], [@CR12], [@CR14]\] have been performed on association between rs1801516 polymorphism and breast cancer risk, and the result for AA vs GG + GA in study of Lu PH et al. \[[@CR14]\] is significant, indicating that AA is a low risk genotype. Our results were consistent with those of Lu et al.. Moreover, 13 studies were included in our meta-analysis of breast cancer, which was much more than that in studies of Mao C et al.(eight studies included) \[[@CR11]\], Gao LB et al. (nine studies included) \[[@CR12]\], and Lu PH et al. (five studies included) \[[@CR14]\]. Thus, compared with GG genotype, AA genotype of rs1801516 may be a potential protective factor of breast cancer. Thirdly, for those with family history, AA homozygotes presented low susceptibility of cancer in our meta-analysis. Impact of family history on cancer occurrence and clinical features has been found in different types of cancer, and family history may also exert an influence on cancer through interaction with gene polymorphism \[[@CR61]--[@CR63]\]. In Mao et al.'s meta-analysis \[[@CR11]\], subgroup analysis was also performed by family history, but their results are not similar to ours. Difference in sample size between the two meta-analyses of ours and Mao et al.'s may result in the inconsistence of results.

In this present meta-analysis, heterogeneity was observed in models of AA+GA vs GG, GA vs GG, and GG + AA vs GA. To find the source of among-studies' heterogeneity, we performed meta-regression analysis by region-specified population, cancer type, source of controls, matched controls or not, family history, sample size, and HWE in controls. As a result, family history was a source of heterogeneity for AA+GA vs GG and GA vs GG models. However, for GG + AA vs GA, none of the analyzed factors was detected as a source of heterogeneity. Lifestyle may be the source of heterogeneity. Lifestyle of the subjects, including smoking and alcohol consumption, influences on their susceptibility to cancer \[[@CR64]--[@CR66]\]. However, the 37 studies included in our meta-analysis do not provide adequate information on lifestyle. Moreover, genotyping methods of the included studies are various: more than ten methods used in all the included studies, and multiple methods were used in several individual studies. Diversity of genotyping methods may also be a reason of heterogeneity, but because of diverse methods, we do not put genotyping methods into the analysis of meta-regression. In addition, matching criteria of the included studies with controls matched to cases are different, giving rise to the heterogeneity possibly.

Meta-analysis may report false positive results for the risk of type I error, and such results are commonly attributed to publication bias, heterogeneity among studies, and low quality of the studies. However, a limited number of trials may not give enough information size, thereby leading to a false estimation \[[@CR67]\]. In order to comprehensively evaluate the impact of *ATM* rs1801516 polymorphism on cancer risk, we performed TSA to reduce the risk of type I error and to estimate whether further studies are required by calculating the required information size. Sample size in our meta-analysis was more than the required information size, indicating that the results of our meta-analyses are reliable and sufficient to draw a conclusion.

We must admit that there are some limitations in our meta-analysis. Firstly, because of the difference in data presentation of age between studies (mean age, median age, and age group), we didn't assess the risk stratified by age. Secondly, environmental factors and life style information were not available for all studies, thus effects of these variables were not taken into consideration. Thirdly, year of data collection may also have an effect on heterogeneity, but not all studies in our meta-analysis provide this information, thus year of data collection was not analyzed in our meta-analysis. Fourthly, 12 types of cancer were included in our meta-analysis. However, only one or two studies were performed on the cancers except breast cancer, thyroid cancer, and cervical cancer, and this may potentially make the result biased.

Conclusions {#Sec17}
===========

In summary, *ATM* rs1801516 polymorphism is not associated with overall cancer risk in total population. However, for subgroup analyses, rs1801516 polymorphism is especially associated with breast cancer risk; in addition, this polymorphism is associated with overall cancer risk in Europeans, South Americans, Asians, and those with family history. Owing to the limitations mentioned above, our results should be interpreted with caution.
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Additional file 1:**Table S1.** Matching criteria and genotyping method of the eligible studies included in the meta-analysis. (DOCX 24 kb)

A-T

:   Ataxia-telangiectasia

ATM

:   Ataxia telangiectasia mutated

CI

:   Confidence interval

DSB

:   Double-strand break

GWAS

:   Genome-wide association studies

HBC

:   Hospital-based controls

HWE

:   Hardy-Weinberg equilibrium

IR

:   Ionizing radiation

MAF

:   Minor allele frequency

NOS

:   Newcastle-Ottawa Scale

OR

:   Odds ratio

PBC

:   Population-based controls

PCR-RFLP

:   PCR-restriction fragment length polymorphism

PI3-K

:   Phosphoinositide 3-kinase

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PTC

:   Papillary thyroid cancer

RT-PCR

:   Real time polymerase chain reaction

SNP

:   Single nucleotide polymorphism

TaqMan

:   TaqManSNP
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